Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 199,050 TG Therapeutics, Inc. (NASDAQ:TGTX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 199,050 shares of TG Therapeutics, valued at approximately $7.85 million, increasing its stake to about 0.13% of the company.
• Goldman Sachs upgraded TG Therapeutics' stock to a "hold" rating with a target price of $37.00, amidst a consensus rating of "Moderate Buy" based on the views of several analysts.
• In a recent quarterly report, TG Therapeutics reported $120.86 million in revenue, marking a 90.4% year-over-year increase, but missed earnings expectations with an EPS of $0.03.

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 199,050 shares of the biopharmaceutical company's stock, valued at approximately $7,849,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.13% of TG Therapeutics at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in TGTX. Norges Bank bought a new stake in TG Therapeutics in the fourth quarter worth $12,085,000. Allspring Global Investments Holdings LLC lifted its position in TG Therapeutics by 54.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock worth $898,000 after buying an additional 8,338 shares during the last quarter. New York State Teachers Retirement System lifted its position in TG Therapeutics by 175.0% in the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock worth $4,746,000 after buying an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in TG Therapeutics in the first quarter worth $226,000. Finally, GAMMA Investing LLC lifted its position in TG Therapeutics by 77.7% in the first quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company's stock worth $179,000 after buying an additional 1,986 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director owned 228,816 shares in the company, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 10.64% of the company's stock.

TG Therapeutics Stock Up 2.7%

Shares of TG Therapeutics stock traded up $0.94 during trading on Wednesday, hitting $36.27. 2,139,612 shares of the stock traded hands, compared to its average volume of 1,418,493. The firm has a market cap of $5.76 billion, a P/E ratio of 151.13 and a beta of 1.91. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. TG Therapeutics, Inc. has a 52-week low of $16.65 and a 52-week high of $46.48. The stock's fifty day simple moving average is $36.79 and its 200 day simple moving average is $35.92.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business's quarterly revenue was up 90.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.07) EPS. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a research note on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $43.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.